Delibera n.2023/1812 Sottosccrizione dell'Addendum n.1 allo studio clinico "A phase III multicenter, randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Fenebritinib compared with Ocrelizumab in adult patients with PrimaryProgressive Multiple Sclerosis"...da condursi presso U.O.C. Neurologia e Strke Unit diretta dal Dott. Salvatore Cottone. (Prop. 78)
| File | Description | File size | Created | Last modified |
|---|---|---|---|---|
 20231812.pdf | 3802 kB | 2023-12-12 11:13 | 2023-12-12 11:13 |